Clinical Trial Update: Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial at MD Anderson evaluating a triple combination of Quizartinib, Decitabine, and Venetoclax for untreated or relapsed acute myeloid leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Decitabine (Decitabine)
• Quizartinib (Quizartinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: RECRUITING